Cancer Institute And Hospital, Chinese Academy Of Medical Sciences

This study tests a new drug combination (iparomlimab and tuvonralimab) plus chemoradiation in 40 people with advanced esophageal cancer that did not improve after initial chemo-immunotherapy. The goal is to see if this approach can help control the cancer and improve survival. Pa…

This early-stage study tests a new gene-editing drug called EDB-102 in 15 adults with advanced non-small cell lung cancer that has spread to the liver and no longer responds to standard targeted therapy. The drug uses CRISPR technology to find and disable a specific cancer-causin…

This study is for women with cervical cancer that has come back or spread and no longer responds to standard immunotherapy. It tests a new combination of two immunotherapy drugs plus chemotherapy, with or without an anti-growth drug. The goal is to see if this combo can shrink tu…

This study tests whether adding the experimental drug QL1706 to standard chemotherapy helps people with advanced triple-negative breast cancer live longer without their disease getting worse. About 78 adults who have already tried one or two prior treatments will be randomly assi…

This study tests whether adding a new antibody (Aitua) to standard chemotherapy before surgery can help remove more cancer in people with advanced high-grade serous ovarian cancer. About 82 newly diagnosed patients whose tumors are hard to fully remove will be randomly assigned t…

This early-phase study tests a new treatment using specially engineered immune cells (CAR-Macrophages) to fight advanced solid tumors that have not responded to standard therapies. About 20 adults with specific tumor markers (like HER2 or PSMA) will receive the cells through an I…

This study compares two treatments for locally advanced cervical cancer: standard chemoradiotherapy versus a new approach using chemotherapy plus immunotherapy (sintilimab) before surgery. The goal is to see if the new combination improves how long patients live without their can…

This early-stage study tests a new experimental drug (BRII-5395) combined with two approved cancer drugs (sintilimab and bevacizumab) in 21 adults with advanced liver cancer linked to chronic hepatitis B. The main goal is to check safety and find the right dose, while also lookin…

This early study tests a new treatment called CAT-101, made from a patient's own immune cells (dendritic cells) loaded with a piece of the cancer-driving KRAS protein. It is given alone or with an immunotherapy drug (tislelizumab) to people with advanced pancreatic cancer or othe…

This study tests a shorter, more intense radiation schedule (hypofractionated radiotherapy) for 60 adults with intermediate-risk head and neck cancer who have had surgery. The goal is to see if this approach is safe and effective at controlling the cancer while reducing late side…

This study tests whether a new drug combination (fruquintinib plus trifluridine/tipiracil) works better than a standard combination (bevacizumab plus trifluridine/tipiracil) for people with advanced colorectal cancer that has not responded to prior treatments. About 292 adults ag…

This study tests a new drug called BR101 in 10 adults with multiple myeloma that has returned or not responded to prior treatments. The main goals are to find the safest dose and check for side effects. Researchers will also look at whether the drug helps shrink or control the ca…

This study tests new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants must have tried standard treatments or have no standard options. The goal is to see if these treatments are safe and shrink tumors, usi…

This study tests two treatments for men with high-risk prostate cancer that hasn't spread. One group gets darolutamide alone, the other gets darolutamide plus hormone therapy. After 3-6 months, all men have surgery to remove the prostate. The goal is to see if the drugs shrink th…

This phase 3 study tests a personalized approach for HER2-positive breast cancer, using genetic and other data to adjust chemotherapy strength before surgery. The goal is to improve tumor shrinkage while reducing side effects. About 2,000 women with early-stage breast cancer will…

This study looks at people with stage II to IIIB non-small cell lung cancer whose tumors shrank after immunotherapy. It compares two surgery approaches: removing only the shrunken tumor area versus removing the original larger area. The goal is to see if less surgery can preserve…

This study tests an experimental drug called sacituzumab tirumotecan in 30 people with advanced pancreatic cancer that has not responded to at least one prior treatment. The drug is given by IV every two weeks and aims to shrink tumors by targeting a protein called TROP-2 found o…

This study tests whether adding the drug adebrelimab to standard chemoradiotherapy helps people with a large, advanced lung cancer that cannot be removed by surgery. About 204 adults aged 18-75 with stage III non-small cell lung cancer will take part. The main goal is to see if t…

This study tests whether adding radiotherapy before surgery to standard chemotherapy can shrink tumors more effectively in people with locally advanced breast cancer. About 50 adults with Luminal or triple-negative breast cancer that didn't shrink enough after initial chemo will …

This study tests two drugs, Glecirasib and Ivonescimab, for people with advanced non-small cell lung cancer that has a specific gene change called KRAS G12C and a protein called PD-L1. The goal is to see if the combination is safe and can shrink tumors. About 42 adults who have n…

This study tests whether giving a short, high-dose course of radiation along with immunotherapy before surgery is safe and effective for people with retroperitoneal sarcoma, a rare cancer in the abdomen. About 28 adults whose tumors are hard to remove completely will receive this…

This study tests a new type of radiation therapy that uses daily MRI scans to track and adjust treatment for large or tricky brain metastases. About 200 people with lung cancer that has spread to the brain will receive this precision approach. The goal is to improve tumor control…

This early-phase study tests a new cell therapy called NEUK203-13 in people with advanced small cell lung cancer or neuroendocrine tumors that have stopped responding to standard treatments. The therapy uses specially engineered immune cells (CAR-NK cells) made from stem cells, w…

This study tests a combination of two treatments for people with a specific type of lung cancer (NSCLC with EGFR mutation) whose cancer has spread to the lining of the brain or spinal cord (leptomeningeal metastasis) after prior targeted therapy. The treatment combines an oral dr…

This study tests an experimental drug called MTM-H-001 in about 69 adults whose B-cell cancers (like certain lymphomas or leukemias) have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, while also seeing if it shrinks tumors…

This study looks at whether women with intermediate-risk breast cancer can safely avoid radiation therapy to the lymph nodes after surgery. About 3,100 participants will be randomly assigned to receive either standard radiation or no radiation. The goal is to see if skipping radi…

This study tests a combination of three drugs (sintilimab, surufatinib, and temozolomide) in 32 people with advanced neuroendocrine carcinoma that has worsened after prior treatment. The goal is to see if the combination can shrink tumors or stop them from growing. Participants r…

This study tests whether adding the immunotherapy drug adebrelimab and/or the targeted drug SHR-A1811 to standard chemotherapy can help more people with HR-positive, HER2-low early breast cancer achieve a complete response (no cancer found at surgery). About 249 participants will…

This study looks at whether it's safe to avoid placing a tube through the nose into the stomach after minimally invasive pancreatic surgery. About 200 adults having this surgery will be randomly assigned to either get the tube or not. The goal is to see if skipping the tube reduc…

This study tests a symptom management program for 252 people recovering from esophageal cancer surgery. The program uses patient feedback to guide care and aims to reduce complications, hospital readmissions, and symptom burden. Participants will use a smartphone app to report sy…

This study tests if a daily whey protein drink can lower the chance of severe mouth sores caused by radiation therapy in people with head and neck cancer. About 504 adults will receive either the protein supplement or a placebo during their radiation treatment. The goal is to see…

This study will track 300 people with advanced lung cancer whose first immunotherapy treatment stopped working. Researchers will observe which second-line treatments doctors choose and how well they work, including survival time and side effects. The goal is to use real-world dat…

This study looks at where cancer spreads to lymph nodes in people with colorectal cancer. Researchers will track 1,200 patients for at least 5 years after surgery to map these patterns. The goal is to help doctors better understand and treat the disease in the future.

This study looks at kidney cancer tumors that have multiple small nodules inside them. Researchers want to find out if these nodules are different from each other and how they might be related. They will use advanced lab tests on tissue from 10 patients to map the genes and cells…

This study is testing a new AI tool called BaiXiaoAi that helps cancer patients, their families, and their doctors communicate better. About 300 adults with cancer will use the AI in a special WeChat group to get information and support. The main goal is to see if the AI gives ac…

This study looks at how the immune environment around bladder tumors changes after chemotherapy or other treatments given before surgery. Researchers will test blood and tissue samples from 30 adults with muscle-invasive bladder cancer to find markers that predict treatment succe…